中国临床药学杂志2024，Vol.33Issue(5)：321-333,13.DOI:10.19577/j.1007-4406.2024.05.001
基于基因变异的呼吸系统疾病多重用药专家共识
Expert consensus on polypharmacy for respiratory diseases guided by genetic polymorphism
摘要
Abstract
Multi-drug combination therapy is frequently used in patients with respiratory diseases.Affected by common drug metabolism enzymes or transporters,multi-drug use is prone to produce drug interactions,which can affect efficacy or lead to adverse drug reactions.The activity of drug metabolism enzymes and transporters and the sensitivity of drug targets are affected by genetic factors,resulting in individual differences in drug efficacy.Therefore,individualized medication regimen adjustment by detecting genes related to drug metabolism combined with clinical efficacy evaluation has gradually become an important means for the risk prevention and control of multi-drug use in clinical multi-disease comorbidities.The Clinical Pharmacy Branch of the Chinese Medical Association organized relevant experts to formulate the Expert Consensus on Multi-drug Use for Respiratory Diseases under the Guidance of Gene Polymorphism based on the latest evidence-based medical or pharmacy results for patients with multiple-drug use for respiratory tract diseases,further promoting its application in the treatment practice of respiratory system clinical diseases,and providing evidence support for medical institutions to make clinical treatment plans.关键词
呼吸系统疾病/多重用药/基因检测/药物相互作用/专家共识Key words
respiratory disease/polypharmacy/genetic testing/drug interaction/expert consensus分类
社会科学引用本文复制引用
中华医学会临床药学专科分会,张健,黄晓会..基于基因变异的呼吸系统疾病多重用药专家共识[J].中国临床药学杂志,2024,33(5):321-333,13.基金项目
国家重点研发计划专项课题(编号2020YFC2005500,2020YFC2005502) （编号2020YFC2005500,2020YFC2005502）
